Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial

BACKGROUND: Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists. ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BJPsych Open
Autors principals: Mayfield, Karla, Siskind, Dan, Winckel, Karl, Hollingworth, Samantha, Kisely, Steve, Russell, Anthony W.
Format: Artigo
Idioma:Inglês
Publicat: The Royal College of Psychiatrists 2015
Matèries:
Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998934/
https://ncbi.nlm.nih.gov/pubmed/27703725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1192/bjpo.bp.115.001073
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars